Correction to: Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial.
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.
Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …
Ultrasound-guided microwave ablation for the treatment of abdominal wall scar endometriosis.
To evaluate the efficacy of ultrasound (US)-guided microwave ablation (MWA) in treating abdominal wall endometriosis (AWE) lesions located at the cesarean scar and to assess the early clinical outcomes of …
Correlation between Polycomb repressive complex proteins and epithelial-mesenchymal transition-associated genes in endometriotic tissues.
Endometriosis is a condition in which functional endometrial glands and stroma are found to grow outside the uterine cavity that can lead to symptoms like dysmenorrhea, dyspareunia, adhesions, and infertility. …